FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043730876> ?p ?o ?g. }

• W2043730876 endingPage "4442" @default.
• W2043730876 startingPage "4429" @default.
• W2043730876 abstract "Leptin is a pleiotropic hormone acting both centrally and peripherally. It participates in a variety of biological processes, including energy metabolism, reproduction, and modulation of the immune response. So far, structural elements affecting leptin binding to its receptor remain unknown. We employed random mutagenesis of leptin, followed by selection of high affinity mutants by yeast surface display and discovered that replacing residue Asp-23 with a non-negatively charged amino acid leads to dramatically enhanced affinity of leptin for its soluble receptor. Rational mutagenesis of Asp-23 revealed the D23L substitution to be most effective. Coupling the Asp-23 mutation with alanine mutagenesis of three amino acids (L39A/D40A/F41A) previously reported to convert leptin into antagonist resulted in potent antagonistic activity. These novel superactive mouse and human leptin antagonists (D23L/L39A/D40A/F41A), termed SMLA and SHLA, respectively, exhibited over 60-fold increased binding to leptin receptor and 14-fold higher antagonistic activity in vitro relative to the L39A/D40A/F41A mutants. To prolong and enhance in vivo activity, SMLA and SHLA were monopegylated mainly at the N terminus. Administration of the pegylated SMLA to mice resulted in a remarkably rapid, significant, and reversible 27-fold more potent increase in body weight (as compared with pegylated mouse leptin antagonist), because of increased food consumption. Thus, recognition and mutagenesis of Asp-23 enabled construction of novel compounds that induce potent and reversible central and peripheral leptin deficiency. In addition to enhancing our understanding of leptin interactions with its receptor, these antagonists enable in vivo study of the role of leptin in metabolic and immune processes and hold potential for future therapeutic use in disease pathologies involving leptin. Leptin is a pleiotropic hormone acting both centrally and peripherally. It participates in a variety of biological processes, including energy metabolism, reproduction, and modulation of the immune response. So far, structural elements affecting leptin binding to its receptor remain unknown. We employed random mutagenesis of leptin, followed by selection of high affinity mutants by yeast surface display and discovered that replacing residue Asp-23 with a non-negatively charged amino acid leads to dramatically enhanced affinity of leptin for its soluble receptor. Rational mutagenesis of Asp-23 revealed the D23L substitution to be most effective. Coupling the Asp-23 mutation with alanine mutagenesis of three amino acids (L39A/D40A/F41A) previously reported to convert leptin into antagonist resulted in potent antagonistic activity. These novel superactive mouse and human leptin antagonists (D23L/L39A/D40A/F41A), termed SMLA and SHLA, respectively, exhibited over 60-fold increased binding to leptin receptor and 14-fold higher antagonistic activity in vitro relative to the L39A/D40A/F41A mutants. To prolong and enhance in vivo activity, SMLA and SHLA were monopegylated mainly at the N terminus. Administration of the pegylated SMLA to mice resulted in a remarkably rapid, significant, and reversible 27-fold more potent increase in body weight (as compared with pegylated mouse leptin antagonist), because of increased food consumption. Thus, recognition and mutagenesis of Asp-23 enabled construction of novel compounds that induce potent and reversible central and peripheral leptin deficiency. In addition to enhancing our understanding of leptin interactions with its receptor, these antagonists enable in vivo study of the role of leptin in metabolic and immune processes and hold potential for future therapeutic use in disease pathologies involving leptin." @default.
• W2043730876 created "2016-06-24" @default.
• W2043730876 creator A5022415049 @default.
• W2043730876 creator A5046669455 @default.
• W2043730876 creator A5047303874 @default.
• W2043730876 creator A5057720896 @default.
• W2043730876 creator A5063789883 @default.
• W2043730876 creator A5065040805 @default.
• W2043730876 creator A5067117251 @default.
• W2043730876 creator A5068608905 @default.
• W2043730876 creator A5082822020 @default.
• W2043730876 creator A5065277105 @default.
• W2043730876 date "2011-02-01" @default.
• W2043730876 modified "2023-10-15" @default.
• W2043730876 title "Development and Characterization of High Affinity Leptins and Leptin Antagonists" @default.
• W2043730876 cites W150631818 @default.
• W2043730876 cites W1564078780 @default.
• W2043730876 cites W1631449371 @default.
• W2043730876 cites W1968918018 @default.
• W2043730876 cites W1970666401 @default.
• W2043730876 cites W1973345523 @default.
• W2043730876 cites W1978450784 @default.
• W2043730876 cites W1988151224 @default.
• W2043730876 cites W1990789777 @default.
• W2043730876 cites W2001194098 @default.
• W2043730876 cites W2002127029 @default.
• W2043730876 cites W2007561747 @default.
• W2043730876 cites W2015546012 @default.
• W2043730876 cites W2018295245 @default.
• W2043730876 cites W2027827094 @default.
• W2043730876 cites W2035770221 @default.
• W2043730876 cites W2040248629 @default.
• W2043730876 cites W2040856989 @default.
• W2043730876 cites W2043304903 @default.
• W2043730876 cites W2056546570 @default.
• W2043730876 cites W2058545695 @default.
• W2043730876 cites W2061390329 @default.
• W2043730876 cites W2066190724 @default.
• W2043730876 cites W2066528365 @default.
• W2043730876 cites W2073104975 @default.
• W2043730876 cites W2073387094 @default.
• W2043730876 cites W2083457167 @default.
• W2043730876 cites W2085408028 @default.
• W2043730876 cites W2100837269 @default.
• W2043730876 cites W2102214369 @default.
• W2043730876 cites W2107994524 @default.
• W2043730876 cites W2108137989 @default.
• W2043730876 cites W2113464653 @default.
• W2043730876 cites W2138096383 @default.
• W2043730876 cites W2144954853 @default.
• W2043730876 cites W2161704600 @default.
• W2043730876 doi "https://doi.org/10.1074/jbc.m110.196402" @default.
• W2043730876 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3039357" @default.
• W2043730876 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21119198" @default.
• W2043730876 hasPublicationYear "2011" @default.
• W2043730876 type Work @default.
• W2043730876 sameAs 2043730876 @default.
• W2043730876 citedByCount "124" @default.
• W2043730876 countsByYear W20437308762012 @default.
• W2043730876 countsByYear W20437308762013 @default.
• W2043730876 countsByYear W20437308762014 @default.
• W2043730876 countsByYear W20437308762015 @default.
• W2043730876 countsByYear W20437308762016 @default.
• W2043730876 countsByYear W20437308762017 @default.
• W2043730876 countsByYear W20437308762018 @default.
• W2043730876 countsByYear W20437308762019 @default.
• W2043730876 countsByYear W20437308762020 @default.
• W2043730876 countsByYear W20437308762021 @default.
• W2043730876 countsByYear W20437308762022 @default.
• W2043730876 countsByYear W20437308762023 @default.
• W2043730876 crossrefType "journal-article" @default.
• W2043730876 hasAuthorship W2043730876A5022415049 @default.
• W2043730876 hasAuthorship W2043730876A5046669455 @default.
• W2043730876 hasAuthorship W2043730876A5047303874 @default.
• W2043730876 hasAuthorship W2043730876A5057720896 @default.
• W2043730876 hasAuthorship W2043730876A5063789883 @default.
• W2043730876 hasAuthorship W2043730876A5065040805 @default.
• W2043730876 hasAuthorship W2043730876A5065277105 @default.
• W2043730876 hasAuthorship W2043730876A5067117251 @default.
• W2043730876 hasAuthorship W2043730876A5068608905 @default.
• W2043730876 hasAuthorship W2043730876A5082822020 @default.
• W2043730876 hasBestOaLocation W20437308761 @default.
• W2043730876 hasConcept C104317684 @default.
• W2043730876 hasConcept C109129352 @default.
• W2043730876 hasConcept C134018914 @default.
• W2043730876 hasConcept C143065580 @default.
• W2043730876 hasConcept C14372207 @default.
• W2043730876 hasConcept C16318435 @default.
• W2043730876 hasConcept C170493617 @default.
• W2043730876 hasConcept C185592680 @default.
• W2043730876 hasConcept C207001950 @default.
• W2043730876 hasConcept C2776885963 @default.
• W2043730876 hasConcept C2780227090 @default.
• W2043730876 hasConcept C2780613262 @default.
• W2043730876 hasConcept C511355011 @default.
• W2043730876 hasConcept C515207424 @default.
• W2043730876 hasConcept C54355233 @default.
• W2043730876 hasConcept C55493867 @default.

• next